The precision
phage platform.
Host-specific lytic technology. Validated in vivo across three peer-reviewed poultry trials. Zero residues. Zero resistance pressure.
Three things antibiotics cannot do.
Bacteriophages were discovered in 1915, suppressed by the rise of antibiotics, and are now the fastest-growing segment in precision animal health. The science behind the commercial advantage is straightforward.
Host-Specific Precision
Each phage binds to specific receptor proteins on the target bacterium's outer membrane. Non-target organisms — beneficial gut flora, probiotics, coccidiostats — are not recognized or harmed. Broad-spectrum antibiotics flatten everything.
Peer-Reviewed Performance
Three peer-reviewed trial documents on file — broilers (n=1,500), layers (n=2,400), and Ma-chicken (n=1,050). FCR improvements up to 7.4% and mortality reductions of 55%.
Zero Residues. Zero Resistance.
Phages self-limit once the target pathogen population collapses — replication ceases when target bacteria fall below threshold density. No tissue residues, no environmental accumulation, no contribution to antimicrobial resistance.
Five steps. One outcome: pathogen eliminated.
Adsorption
Phage binds to specific receptor proteins on the target bacterium. Non-target organisms are not recognized.
Injection
Phage DNA enters the bacterial cell, leaving the capsid outside.
Replication
Host cell machinery is redirected to produce 50–200 new phage particles per cycle.
Lysis
Bacterial cell wall ruptures. Progeny phages are released and propagate through the remaining pathogen population.
Self-Limitation
Once pathogen density falls below threshold, phage replication ceases. No accumulation. No residues.
Seven SKUs. Three application categories.
Each product is a distinct formulation designed for a specific species, pathogen profile, and customer type. The poultry line spans farm-ready finished goods to high-titer concentrates for feed manufacturers.
Headline metrics — three peer-reviewed trials.
The E. coli + Salmonella phage backbone is validated in vivo. All metrics below are from published studies with authorized English translations on file.
1.63 → 1.51 (control → PHAGIX)
Outperformed antibiotic comparator
2.51% → 1.07%
Enhanced immune activation
Source: Ge L. et al., Feed Research 2020 (04) 111–115; 2020 (07); 2022 (07). Authorized translations on file. View full evidence library
Contact a PHAGIX specialist.
Platform overview, product datasheets, authorized trial translations, and the PHAGIX Introduction Book (28-page portfolio). Our team provides product selection guidance for your species, pathogen challenge, and inclusion program.